about
A dual function fusion protein of Herpes simplex virus type 1 thymidine kinase and firefly luciferase for noninvasive in vivo imaging of gene therapy in malignant gliomaTranscranial Doppler sonography in adult hydrocephalic patients.Back to the roots of modern neurosurgery: neurosurgical pioneers in Halle an der Saale.Absence of p53 autoantibodies in sera from glioma patients.Clinical development of experimental therapies for malignant glioma.Experimental strategies for combined suicide and immune cancer gene therapy. An overview.Motor cortex stimulation for neuropathic facial pain.Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease.Gene therapy for human malignant brain tumors.Oncolytic viruses for treatment of malignant brain tumours.Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomasTechnology evaluation: cintredekin besudotox, NeoPharm/Nippon.Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.Management of chronic back and leg pain by intrathecal drug delivery.Dual electrode spinal cord stimulation in chronic leg and back pain.Hardware failures in spinal cord stimulation (SCS) for chronic benign pain of spinal origin.Receptor tyrosine kinases as therapeutic targets in malignant glioma.Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma.Targeted biological therapies for pain.Clinical development of experimental virus-mediated gene therapy for malignant glioma.Making a case for programmable pumps over fixed rate pumps for the management of fluctuations in chronic pain and spasticity: a literature review.Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin.MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status.Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.Overall survival in patients with malignant glioma may be significantly longer with tumors located in deep grey matter.Thoracic and lumbar meningocele in neurofibromatosis type 1. Report of two cases and review of the literature.A neuroblastoma-selective suicide gene therapy approach using the tyrosine hydroxylase promoter.The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells.Hypoxia-inducible transgene expression in differentiated human NT2N neurons--a cell culture model for gene therapy of postischemic neuronal loss.Identification of genotoxic stress in human cells by fluorescent monitoring of p53 expression.Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma.Intracellular localization of Herpes simplex virus type 1 thymidine kinase fused to different fluorescent proteins depends on choice of fluorescent tag.Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.Gamma-glutamyl transferase expression in higher-grade astrocytic glioma.Long-term intrathecal infusion of drug combinations for chronic back and leg pain.Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.Systemic activation of the immune system during ganciclovir treatment following intratumoral herpes simplex virus type 1 thymidine kinase gene transfer in an adolescent ependymoma patient.Abdominal CSF pseudocysts in patients with ventriculo-peritoneal shunts. Report of fourteen cases and review of the literature.
P50
Q24802324-B4A96006-F5FD-42B8-88E7-9DF7D85F7D70Q30321124-A615EBA2-EBC5-4457-8F86-C530B1ADFAC9Q30321357-CEC8585D-8AD2-47FB-B521-7FF6FE53E1F5Q30321390-23C6AEF5-78D2-4580-BE9F-698BC4648D5AQ34782295-8A8BCA0A-1886-4B5B-8635-1801E6BB6345Q35038562-7B518108-2797-4184-B7F7-D8D82E447476Q35084922-0237DF3E-1C3E-4726-BBC0-E735F1244DEEQ35146654-15FE6A13-2FAE-42C0-86E5-82C08ED493B2Q35210470-232C97D5-787A-43CF-89C4-C1539AC02C54Q35553135-2D187A47-C06F-4DC6-950C-919909717DFEQ35827956-4C7292D5-8C79-4AD8-9C63-8C4AC42D47F6Q36103853-0C8AFD7F-FA69-4B57-A4D4-2AF01E195F51Q36296515-46C86CA6-AD46-4EB2-8FA4-0D25B20070D2Q36906970-CB4A5D0A-143F-4DED-B01C-79D0CB68087BQ36906980-6FE45FC5-1B9C-4AA2-B9B6-AE9DDEC4D337Q36906982-35D208EC-580A-4D3F-83B5-AC15003E3A52Q37161247-187D6838-0ECD-4B14-9119-86B3ACFD48D2Q37161306-5C74153C-CB73-4F1E-A38D-47A81D97648FQ37882724-8C504A52-E301-41DB-8067-84E7345C0D69Q37894782-3CDEC4A5-0D74-4143-BE16-03607F299434Q37965990-74FCB88D-1198-4809-97F9-32E0A6A670FCQ38922636-5B51ED48-7C10-4AB1-BFCC-DC7E8D44496AQ39528026-49C2E8FD-9B15-455E-9CE3-4918A6FFA468Q39620715-FE37559F-8488-4349-A62E-D061E966FD60Q39892514-C64CB79C-6470-4426-8CB1-2EF4C4DAA003Q40216953-ABC63494-D92D-4602-94E6-6D8EA17762C8Q40369966-DFD67DF3-3F4B-4A47-B171-3596CC1FBCEFQ40548567-40AA1B45-5971-44A6-8A70-FF3073154B11Q40653480-99BF0158-CDEC-4695-9CDA-1B3973F08421Q40778617-D0AE3536-EDFD-44AC-BFFF-3ED7A7A9F552Q40796791-F800A2EE-6815-4AEF-8820-E35AA2183824Q40865020-5B72BD57-C84B-4214-9ED1-CE34E5A29B2DQ42810573-8B84CC98-B6A8-4399-8684-397E3D98957DQ43636591-C17353CE-C204-465F-91C9-726E0DC53192Q43706482-9EFCCB2D-188C-4CCA-BF82-B360AAF882E3Q43750736-9A117785-98DF-406A-A66D-0D9B7FD1B33FQ43761368-0EE65093-9AC3-4046-9516-E574B0958EE5Q43866864-A16D7F2E-0202-4264-8E3B-96B20ADC3E7FQ43945636-3EE17C5B-263F-4F61-992A-04DC8E40AD6FQ44209230-52554619-397A-47FF-B287-32EB63C35385
P50
description
researcher
@en
wetenschapper
@nl
name
Nikolai G. Rainov
@en
Rainov NG
@ast
Rainov NG
@nl
type
label
Nikolai G. Rainov
@en
Rainov NG
@ast
Rainov NG
@nl
altLabel
Rainov NG
@en
prefLabel
Nikolai G. Rainov
@en
Rainov NG
@ast
Rainov NG
@nl
P106
P31
P496
0000-0001-7858-9415